Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Oct 20, 2020

Sanofi and Merck to present three new studies highlighting combination pediatric vaccines at IDWeek 2020
Oct 13, 2020

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
Oct 1, 2020

Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D)

- Healthcare professional and patient campaigns focus on screening for early-stage T1D-
Sep 30, 2020

Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

- Expect to complete filing of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 -
Sep 21, 2020

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.